JP2014504851A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014504851A5 JP2014504851A5 JP2013540008A JP2013540008A JP2014504851A5 JP 2014504851 A5 JP2014504851 A5 JP 2014504851A5 JP 2013540008 A JP2013540008 A JP 2013540008A JP 2013540008 A JP2013540008 A JP 2013540008A JP 2014504851 A5 JP2014504851 A5 JP 2014504851A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- seq
- polypeptide
- bacterium
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 229920001184 polypeptide Polymers 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 241000894006 Bacteria Species 0.000 claims 6
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000001018 virulence Effects 0.000 claims 3
- 241000186779 Listeria monocytogenes Species 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000003248 secreting effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 108020004705 Codon Proteins 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 108700016271 Listeria monocytogenes actA Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims 1
- 101100385342 Synechocystis sp. (strain PCC 6803 / Kazusa) cry gene Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 101150046348 inlB gene Proteins 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 102000006240 membrane receptors Human genes 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 101150036926 phrB gene Proteins 0.000 claims 1
- 101150079601 recA gene Proteins 0.000 claims 1
- 101150005573 uvrA gene Proteins 0.000 claims 1
- 101150060445 uvrB gene Proteins 0.000 claims 1
- 101150003576 uvrC gene Proteins 0.000 claims 1
- 101150073340 uvrD gene Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41485010P | 2010-11-17 | 2010-11-17 | |
| US61/414,850 | 2010-11-17 | ||
| PCT/US2011/061164 WO2012068360A1 (en) | 2010-11-17 | 2011-11-17 | Methods and compositions for inducing an immune response to egfrviii |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014504851A JP2014504851A (ja) | 2014-02-27 |
| JP2014504851A5 true JP2014504851A5 (enExample) | 2015-01-08 |
| JP5998370B2 JP5998370B2 (ja) | 2016-09-28 |
Family
ID=46084412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013540008A Expired - Fee Related JP5998370B2 (ja) | 2010-11-17 | 2011-11-17 | Egfrviiiに対する免疫応答を誘発する方法および組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9200057B2 (enExample) |
| EP (1) | EP2640842B1 (enExample) |
| JP (1) | JP5998370B2 (enExample) |
| CN (1) | CN103415620B (enExample) |
| CA (1) | CA2818353A1 (enExample) |
| CY (1) | CY1120622T1 (enExample) |
| DK (1) | DK2640842T3 (enExample) |
| ES (1) | ES2684684T3 (enExample) |
| HR (1) | HRP20181343T1 (enExample) |
| HU (1) | HUE039747T2 (enExample) |
| LT (1) | LT2640842T (enExample) |
| PL (1) | PL2640842T3 (enExample) |
| PT (1) | PT2640842T (enExample) |
| RS (1) | RS57630B1 (enExample) |
| SI (1) | SI2640842T1 (enExample) |
| SM (1) | SMT201800444T1 (enExample) |
| WO (1) | WO2012068360A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2857499A1 (en) | 2010-10-01 | 2015-04-08 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DK2640842T3 (en) * | 2010-11-17 | 2018-08-13 | Aduro Biotech Inc | Methods and compositions for inducing an immune response to EGFRVIII |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| EP2858722B8 (en) | 2012-06-08 | 2018-02-21 | Aduro BioTech, Inc. | Compostions and methods for cancer immunotherapy |
| CA2888678A1 (en) | 2012-11-06 | 2014-05-15 | Aduro Biotech, Inc. | Facultatively attenuated bacterial species and methods of preparation and use thereof |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| SG11201502796RA (en) | 2012-12-13 | 2015-05-28 | Aduro Biotech Inc | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| AU2013370210B2 (en) | 2012-12-27 | 2018-06-14 | Aduro Biotech, Inc. | Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| CN105377867B (zh) | 2013-05-03 | 2019-11-12 | 加利福尼亚大学董事会 | I型干扰素的环状二核苷酸诱导 |
| EP2996472B1 (en) | 2013-05-18 | 2019-03-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
| CU24377B1 (es) | 2013-05-18 | 2018-12-05 | Aduro Biotech Inc | Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| AU2015250111A1 (en) * | 2014-04-24 | 2016-12-08 | Advaxis, Inc. | Recombinant listeria vaccine strains and methods of producing the same |
| US10925945B2 (en) | 2014-10-13 | 2021-02-23 | Providence Health & Services-Oregon | Bacterial vaccines deficient in the 2-C-methyl-D-erythritol-4-phosphate pathway and methods of preparation and use thereof |
| SG11201702857PA (en) * | 2014-10-14 | 2017-05-30 | Univ Pennsylvania | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy |
| WO2016073381A1 (en) | 2014-11-03 | 2016-05-12 | Cerus Corporation | Compositions and methods for improved car-t cell therapies |
| TWI706958B (zh) | 2015-03-10 | 2020-10-11 | 美商艾杜諾生物科技公司 | 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法 |
| HK1250662A1 (zh) * | 2015-04-13 | 2019-01-11 | Aduro Biotech, Inc. | 用於治疗癌症的免疫原性融合蛋白 |
| CA2982533A1 (en) * | 2015-04-13 | 2016-10-20 | Aduro Biotech, Inc. | Epidermal growth factor receptor variant iii-mesothelin fusions and methods of using the same |
| US10455265B2 (en) * | 2015-04-27 | 2019-10-22 | Ericsson Ab | Program and device class entitlements in a media platform |
| TW201708536A (zh) * | 2015-05-26 | 2017-03-01 | 艾法西斯公司 | 個人化的基於遞送載體之免疫療法及其用途 |
| EP3313975A4 (en) * | 2015-06-24 | 2019-03-13 | Advaxis, Inc. | MANUFACTURING DEVICE AND METHOD FOR PERSONALIZED ADMINISTRATION OF VECTOR-BASED IMMUNOTHERAPY |
| JP7114477B2 (ja) | 2015-12-16 | 2022-08-08 | グリットストーン バイオ インコーポレイテッド | 新生抗原の特定、製造、および使用 |
| NL2017267B1 (en) | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
| EP3491009A4 (en) * | 2016-08-01 | 2020-03-04 | Aduro BioTech, Inc. | Protein expression enhancer sequences and use thereof |
| NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
| CN111465989B (zh) | 2017-10-10 | 2024-06-25 | 磨石生物公司 | 使用热点进行的新抗原鉴别 |
| AU2018373154B2 (en) | 2017-11-22 | 2025-08-07 | Seattle Project Corp. | Reducing junction epitope presentation for neoantigens |
| WO2021014398A1 (en) * | 2019-07-23 | 2021-01-28 | University Of Rijeka Faculty Of Medicine | Integrated human cytomegalovirus / glioblastoma vaccine |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830702A (en) | 1990-10-31 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response |
| US5856457A (en) | 1991-03-29 | 1999-01-05 | Genentech, Inc. | Nucleic acids encoding a human IL-8 receptor |
| IT1262895B (it) | 1992-03-02 | 1996-07-22 | Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico. | |
| US6379943B1 (en) | 1999-03-05 | 2002-04-30 | Merck & Co., Inc. | High-efficiency Cre/loxp based system for construction of adenovirus vectors |
| US5709999A (en) * | 1994-08-12 | 1998-01-20 | Myriad Genetics Inc. | Linked breast and ovarian cancer susceptibility gene |
| US7794729B2 (en) * | 1994-11-08 | 2010-09-14 | The Trustees Of The University Of Pennsylvania | Methods and compositions for immunotherapy of cancer |
| US6051237A (en) | 1994-11-08 | 2000-04-18 | The Trustees Of The University Of Pennsylvania | Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector |
| ATE262586T1 (de) | 1994-11-28 | 2004-04-15 | Univ Jefferson | Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin |
| US5888530A (en) | 1995-07-21 | 1999-03-30 | The General Hospital Corporation | Method of enhancing delivery of a pharmaceutical formulation |
| US6099848A (en) | 1997-11-18 | 2000-08-08 | The Trustees Of The University Of Pennsylvania | Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use |
| US8021658B2 (en) * | 2001-05-25 | 2011-09-20 | Thomas Jefferson University | Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| WO2003102168A1 (en) | 2002-05-29 | 2003-12-11 | The Regents Of The University Of California | Attenuated listeria spp. and methods for using the same |
| US20050175625A1 (en) | 2002-07-12 | 2005-08-11 | The Johns Hopkins University | Mesothelin vaccines and model systems |
| KR101173871B1 (ko) | 2003-02-06 | 2012-08-16 | 앤저 테라퓨틱스 인코퍼레이티드 | 변형된 독립생존 미생물, 백신 조성물 및 그것의 사용방법 |
| ATE552843T1 (de) | 2003-02-06 | 2012-04-15 | Aduro Biotech | Listerien deren eindringen in nicht-phagozytische zellen abgeschwächt ist, impfstoffe, die diese listerien enthalten und deren verwendungen |
| US7842289B2 (en) | 2003-12-24 | 2010-11-30 | Aduro Biotech | Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof |
| DK1940461T3 (da) * | 2005-11-02 | 2014-03-31 | Univ Duke | Samtidig kemoterapi og immunterapi |
| WO2007117371A2 (en) | 2006-03-01 | 2007-10-18 | Anza Therapeutics, Inc. | Engineered listeria and methods of use thereof |
| GB2451014B (en) * | 2006-03-01 | 2010-12-29 | Anza Therapeutics Inc | Engineered Listeria comprising a modified ActA-antigen fusion protein and its use as a vaccine |
| US8900816B2 (en) * | 2007-07-19 | 2014-12-02 | Duke University | Assay for anti-EGFRvIII antibodies |
| CA2724649A1 (en) * | 2008-05-19 | 2009-11-26 | Anza Therapeutics, Inc. | Compositions comprising prfa* mutant listeria and methods of use thereof |
| KR20110045010A (ko) * | 2008-07-24 | 2011-05-03 | 아두로 바이오테크 | C형 간염의 치료를 위한 조성물 및 방법 |
| TWI543767B (zh) * | 2008-08-19 | 2016-08-01 | 腫瘤療法 科學股份有限公司 | Hig2與urlc10抗原決定位胜肽以及含此胜肽之疫苗 |
| DK2640842T3 (en) * | 2010-11-17 | 2018-08-13 | Aduro Biotech Inc | Methods and compositions for inducing an immune response to EGFRVIII |
-
2011
- 2011-11-17 DK DK11841347.5T patent/DK2640842T3/en active
- 2011-11-17 EP EP11841347.5A patent/EP2640842B1/en active Active
- 2011-11-17 US US13/988,076 patent/US9200057B2/en not_active Expired - Fee Related
- 2011-11-17 LT LTEP11841347.5T patent/LT2640842T/lt unknown
- 2011-11-17 SI SI201131548T patent/SI2640842T1/sl unknown
- 2011-11-17 HU HUE11841347A patent/HUE039747T2/hu unknown
- 2011-11-17 PT PT11841347T patent/PT2640842T/pt unknown
- 2011-11-17 PL PL11841347T patent/PL2640842T3/pl unknown
- 2011-11-17 CA CA2818353A patent/CA2818353A1/en not_active Abandoned
- 2011-11-17 CN CN201180062129.XA patent/CN103415620B/zh not_active Expired - Fee Related
- 2011-11-17 RS RS20180979A patent/RS57630B1/sr unknown
- 2011-11-17 WO PCT/US2011/061164 patent/WO2012068360A1/en not_active Ceased
- 2011-11-17 SM SM20180444T patent/SMT201800444T1/it unknown
- 2011-11-17 ES ES11841347.5T patent/ES2684684T3/es active Active
- 2011-11-17 HR HRP20181343TT patent/HRP20181343T1/hr unknown
- 2011-11-17 JP JP2013540008A patent/JP5998370B2/ja not_active Expired - Fee Related
-
2015
- 2015-11-25 US US14/952,470 patent/US9775891B2/en not_active Expired - Fee Related
-
2017
- 2017-10-02 US US15/722,908 patent/US20180021420A1/en not_active Abandoned
-
2018
- 2018-08-27 CY CY181100893T patent/CY1120622T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016503655A5 (enExample) | ||
| JP2010508861A (ja) | 抗原およびタンパク質毒素をコードする異種ヌクレオチド配列からなる担体としての微生物、その生成方法、ならびにその使用 | |
| CN102046198A (zh) | 鞭毛蛋白多肽疫苗 | |
| CN112979829B (zh) | 融合蛋白及其在制备靶向新冠病毒sars-cov-2的疫苗中的应用 | |
| RU2677799C2 (ru) | Модифицированные суперспиральные белки с улучшенными свойствами | |
| KR20160130216A (ko) | 헤테로올리고머 미코박테리아 항원의 융합물 | |
| JP2011529077A (ja) | C型肝炎の治療のための組成物および方法 | |
| JP2009540801A5 (enExample) | ||
| JP2014507146A5 (enExample) | ||
| TWI621627B (zh) | 用於豬生殖與呼吸綜合症及豬環狀病毒關聯疾病之疫苗組成物 | |
| CN103013954B (zh) | 水稻基因badh2的定点敲除系统及其应用 | |
| WO2007125535A1 (en) | Recombinant flagellin gene and uses thereof | |
| US20150017198A1 (en) | Mutated and bacteriophage t4 nanoparticle arrayed f1-v immunogens from yersinia pestis as next generation plague vaccines | |
| US9925259B2 (en) | Immunogenic polypeptide surface layer-expressing bifidobacterium | |
| CN107723269B (zh) | 重组鼠伤寒沙门菌二价疫苗株的构建方法及所得株和应用 | |
| WO2022034221A1 (en) | Salmonella vaccine for the treatment of coronavirus | |
| CA2730741C (en) | Self-replicating vector lacking an antibiotic-resistance gene | |
| Kim et al. | Oral administration of Lactococcus lactis expressing Helicobacter pylori Cag7-ct383 protein induces systemic anti-Cag7 immune response in mice | |
| EP3562504B1 (en) | Dna vaccine comprising a polynucleotide sequence encoding a fusion protein encompassing a plant protein signal sequence | |
| Aguilera et al. | Porcine circovirus type 2 protective epitope densely carried by chimeric papaya ringspot virus–like particles expressed in Escherichia coli as a cost‐effective vaccine manufacture alternative | |
| CN104127883B (zh) | 以hsp65为表位支架的多t细胞表位结核基因疫苗 | |
| WO2009127766A1 (es) | Sistema para la expresión de péptidos sobre la superficie bacteriana | |
| US20240254167A1 (en) | Genetically modified clostridium strains expressing recombinant antigens and uses thereof | |
| CN106170551B (zh) | 生产不耐热肠毒素b亚单位的质粒、方法及其套组 | |
| EP3302545A1 (en) | The strain of gram-positivebacillus subtilis |